EUCTR2010-019110-24-DE进行中（未招募）不适用
A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS - ZOLEHO
niversitätsklinikum Erlangen0 个研究点开始时间: 2010年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.1.Must understand and voluntarily sign an informed consent form
- •2.Male or female, must be aged = 18 years at time of consent
- •3.Must have a diagnosis of erosive hand osteoarthritis according to ACR criteria for at least six months
- •4.Must have at least two bone erosions detectable in conventional radiographs of the hands at the first carpo-metacarpal joint (CMC) and/or proximal and/or distal interphalangeal joints (radiographs must not be older than one year).
- •5.Must have active disease at screening with at least two swollen and tender proximal interphalangeal (PIP) and/or distal interphalangeal (DIP) joints
- •6.Must have a value of at least 40 on the VAS in the patient self-assessment of pain at screening
- •7.Must have negative serum rheumatoid factor (RF) and cyclic ciytrulinated peptide antibody (CCP)
- •8.Must be able to adhere to the study visit schedule and other protocol requirements
- •9.Females must be postmenopausal for at least 24 consecutive months or must have undergone a hysterectomy or bilateral oophorectomy
- •10.Must meet the following laboratory criteria:
- •?Haemoglobin = 9 g/dL
- •?Haematocrit = 27%
- •?White blood cell (WBC) count = 3,000/µL (= 3.0 X 109/L) and = 14,000/µL (= 14 X 109/L)
- •?Neutrophils = 1,500/µL (= 1.5 X 109/L)
- •?Platelets = 100,000/µL (= 100 X 109/L)
- •?Serum creatinine = 1.5 mg/dL (= 132.6 µmol/L)
- •?Creatinine clearance = 35 ml/min
- •?Total billirubin = 2.0 mg/dL
- •?Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) = 1.5x upper limit of normal (ULN)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.1.History of malignancy within the previous 5 years
- •2.History of any clinically significant cardiac, endocrine, pulmonary, neurological, psychiatric, hepatic, renal, haematological, immunologic, or other major disease
- •3.Any clinically significant abnormality on 12-lead ECG at screening
- •4.History of parathyroid surgery or malabsorption of any kind including previous resection of the small intestine
- •5.History of or treatment for aspirin-sensitive bronchial asthma
- •6.Planned dental surgery within the following 12 months from Day 1 of the study
- •7.Human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection
- •8.History of serious infections (e.g. pneumonia, pyelonephritis) in the previous 3 months
- •9.History of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study medication administration, or may interfere with interpretation of results
- •10.Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- •11.Laboratory finding of hypocalcaemia at screening or current treatment for hypocalcaemia
- •12.History of any clinically significant inflammatory disease other than EHOA, especially, but not limited to, rheumatoid arthritis or spondylarthropathies
- •13.History or diagnosis of fibromyalgia
- •14.Evidence of gout, pseudogout or haemochromatosis
- •15.Evidence of calcium pyrophosphate deposition disease ( CPPD)
- •16.Significant injury to the affected joint within six months prior to screening
- •17.History of infected joint or joint prosthesis within the previous 5 years
- •18.Any anti-inflammatory or immunosuppressive therapy for any condition including, but not limited to glucocorticoids, methotrexate, sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds, penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, and azathioprine within 35 days prior to randomization
- •19.Use of aminoglycoside antibiotics, loop diuretics and any other nephrotoxic drugs within 35 days prior to randomization
- •20.Use of NSAIDs within seven days prior to screening
- •21.Intra-articular injection of corticosteroids three months prior to randomization
- •22.Intra-articular injection of hyaluronate within six month prior to randomization
- •23.Use of any investigational medication within six months prior to randomization
- •24.Use of nutriceuticals” and alternative medicine products, if not taken in a stable dose for a minimum of three month prior to randomization
- •25.Patients not able to take daily calcium and vitamin D supplements
- •26.Patients who participated in this study before
- •27.Patients who possibly are dependent on the sponsor or investigator
- •28.Patients who have not given consent to the sharing of their pseudonymized data according to §§7(2)15, 12 and 3 GCP-V
研究者
相似试验
进行中（未招募）
1 期
A PHASE II, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RESPONSE, STUDY TO ASSESS THE CLINICAL BENEFIT OF DROXIDOPA AND DROXIDOPA/CARBIDOPA IN SUBJECTS WITH FIBROMYALGIATreatment of pain associated with fibromyalgiaMedDRA version: 9.1 Level: LLT Classification code 10048439 Term: FibromyalgiaEUCTR2008-001123-62-GBChelsea Therapeutics Inc.
招募中
2 期
A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NAB-PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1 POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCERC50 Cancer de mamaPER-019-23F. HOFFMANN-LA ROCHE LTD.12
招募中
1 期
A Study of RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerCTIS2022-502457-34-00F. Hoffmann-La Roche AG160
进行中（未招募）
1 期
A blinded phase II study to evaluate the efficacy and safety of 2 different treatments arms (RO5520985 plus standard chemotherapy FOLFOX versus bevacizumab plus standard chemotherapy FOLFOX) in patients who have not been treated before for their metastatic disease of colorectal cancer.Patients with cancer of the colon or rectum where the tumor has already spread to other organs(s),MedDRA version: 19.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10055097Term: Rectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10055114Term: Colon cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005108-32-GBF. Hoffmann-La Roche Ltd190
尚未招募
2 期
A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH PEMBROLIZUMAB COMBINED WITH NAB-PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1*POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCERTNBC10006291Breast cancerNL-OMON53202Roche Nederland B.V.2